Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsDog Arthritis Treatment Under Fire After Reports of Severe, Even Fatal, Side Effects refers to Librela (bedinvetmab), a monthly prescription injection for pain associated with canine osteoarthritis. Regulators have documented reports of neurologic and immune-mediated problems, worsening joint disease, and deaths, but spontaneous reports do not prove Librela caused every event or establish a fatality rate.
Librela is not a supplement and is not a general-purpose arthritis remedy. The medicine is an anti-nerve-growth-factor monoclonal antibody given by weight-based subcutaneous injection, usually once monthly, under veterinary supervision.
The important distinction is between reported after treatment and proven caused by treatment. The FDA and the UK Veterinary Medicines Directorate have identified serious reports and continued surveillance, while also warning that missing medical histories, concurrent medicines, underlying illness, reporting bias, and the absence of a dependable treated-dog denominator make the risk difficult to quantify.
Key takeaways
- Librela (bedinvetmab) is a prescription, weight-based subcutaneous injection given monthly for pain associated with canine osteoarthritis; the U.S. FDA approved Librela on May 5, 2023.
- According to the FDA’s 2024 review, 3,674 total Librela-associated cases, including 3,637 cases in dogs, were reported from approval through March 31, 2024; 120 cases in a focused set recorded death or euthanasia as an outcome, but the figure is not a fatality rate.
- According to the FDA’s report published July 14, 2026, 18,056 adverse-drug-event reports across species, including 17,779 reports in dogs, had been recorded through June 30, 2026; report totals cannot establish incidence or causation.
- The UK Veterinary Medicines Directorate estimated death reports at 1 to 10 animals per 10,000 estimated animals treated and rapidly progressive joint-disease reports at fewer than 1 animal per 10,000, while emphasizing that causation was uncertain in many cases.
- UK product information updated in January and February 2026 lists very rare reports of paresis, paralysis, seizures, immune-mediated diseases, and hypersensitivity reactions, and advises caution in dogs with certain pre-existing immune-mediated conditions.
- Veterinary arthritis care is usually multimodal: weight management, controlled exercise, rehabilitation, environmental changes, nutrition, and carefully selected medication may all have a role.
What is Librela and why is it under fire?
Librela is the brand name for bedinvetmab, an anti-nerve-growth-factor monoclonal antibody used by veterinarians to reduce pain associated with canine osteoarthritis. Librela is administered as a weight-based subcutaneous injection once a month. Librela is a prescription veterinary medicine, not a general-purpose arthritis supplement.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
#1 Best Overall
- Health Supplement for Dogs: VetIQ hip and joint chews for dogs are soft and a great way to support mobility, whether they love running, jumping, playing, or resting; They suit senior pets or those who need extra support staying active & comfortable
- Joints, Mobility, & Bone Health: Our Hip & Joint soft chews, senior dog treats, are designed to support hip mobility & overall joint health; every bite helps enhance bone health, maintain strong muscles, and ease stiffness from normal daily exercise
- High-Quality Ingredients: Made with a careful selection of high-quality ingredients, our dog joint supplement formula includes omegas to help lubricate joints, glucosamine supporting healthy joints and mobility, and MSM maintaining healthy muscles
- Chicken Flavored: Packed with a tasty chicken flavor that pups find irresistible, each soft chew is both beneficial and delicious, made with dog glucosamine to support your dog’s health
- Veterinarian Recommended: VetIQ hip & joint supplements for dogs are trusted by veterinarians and NASC-certified, ensuring quality, safety, and effectiveness; Feel confident adding these Hip & Joint soft chews to your dog’s daily wellness routine
The U.S. Food and Drug Administration approved Librela on May 5, 2023. In a December 16, 2024 Dear Veterinarian letter, the FDA described post-market reports involving neurologic signs, urinary incontinence, excessive urination or thirst, and deaths or euthanasia in some cases.
The concern is therefore real in the sense that regulators have received and reviewed serious reports. The evidence does not justify the broader claim that Librela has been proven to cause widespread fatal toxicity, or that every seizure, weak leg, worsening joint problem, or death reported after an injection was caused by Librela.
What did the FDA’s Librela review find?
The FDA’s focused review found a safety signal worth communicating to veterinarians, but the review was based on spontaneous adverse-event reports rather than a controlled study of all treated dogs. Spontaneous reports are useful for detecting possible patterns after a medicine reaches the market, but they do not provide a dependable number of dogs exposed to the medicine or a matched untreated comparison group.
According to the FDA’s 2024 pharmacovigilance review, the agency examined 3,674 total cases associated with Librela from the May 5, 2023 approval through March 31, 2024. The cases included 3,637 reports involving dogs. Within a focused group of 363 cases involving signs of concern, death, including euthanasia, was reported as an outcome in 120 cases. The 120 cases came from a selected safety-signal group, not from all dogs that received Librela.
The FDA’s later adverse-event report covering records through June 30, 2026 lists 18,056 reports across species, including 17,779 reports in dogs. The FDA states that a clinical sign may be reported more than once in a case and that accumulated reports should not be used to calculate incidence or compare Librela’s safety with another product.
| FDA evidence | What was recorded | What the figure does not show |
|---|---|---|
| Focused review, 2024 | 3,674 total Librela-associated cases; 3,637 involved dogs. | The number of treated dogs, the percentage affected, or the percentage caused by Librela. |
| Focused signs-of-concern group, 2024 | 363 cases were assessed; death or euthanasia was reported in 120 cases. | A 120-in-363 fatality rate, because the cases were selected for concerning signs and causation was not established for every report. |
| Timing in reviewed death-report cases, 2024 | 94 cases followed the initial dose; 82 included reported concomitant product use; onset ranged from one day to more than one month. | A predictable time-toxicity pattern or proof that the first dose or another medicine caused the outcome. |
| Cumulative report search through June 30, 2026 | 18,056 reports across species, including 17,779 reports in dogs. | A population incidence, a fatality rate, or a valid product-to-product safety ranking. |
These distinctions matter. A high-severity report can warrant investigation even when the report cannot establish causation. Conversely, the absence of a confirmed causal determination in an individual report does not mean the dog’s experience should be dismissed.
Has Librela caused deaths in dogs?
Deaths and euthanasia have been reported after Librela treatment, but the available regulatory evidence does not establish a reliable population fatality rate or prove that Librela caused every reported death.
Rank #2
- MOBILITY YOUR DOG CAN FEEL: Help your dog run, jump, and take the stairs like they used to. This daily formula supports healthy cartilage, cushioned joints, and easy everyday movement for dogs of every breed and age.
- FOUR JOINT INGREDIENTS, NOT JUST ONE: Each chew combines glucosamine and chondroitin with MSM and hyaluronic acid, four joint-supporting ingredients working together for connective tissue and comfortable motion.
- A CHEW THEY THINK IS A TREAT: A savory liver flavor dogs love, so daily joint support becomes something they look forward to instead of a pill you have to hide.
- MADE FOR AGING AND ACTIVE DOGS: Ideal for seniors slowing down, larger breeds prone to joint stress, and active dogs you want to keep limber and mobile for years to come.
- 90 SOFT CHEWS, TRUSTED FOR 34+ YEARS: A full supply of daily joint support, made in the USA from domestic and globally sourced ingredients in an FDA-registered facility and quality-tested by a brand families have trusted for over three decades.
In its February 16, 2026 assessment, the UK Veterinary Medicines Directorate estimated death reports at 1 to 10 animals per 10,000 estimated animals treated. That estimate describes reported deaths relative to an estimated treated-animal denominator. It is not the same as saying that Librela caused 1 to 10 deaths per 10,000 dogs.
The VMD identified a small subset of dogs aged six years or older that deteriorated rapidly within 14 days of administration. The agency found no consistent pattern in the symptoms or the number of doses received and said many reports did not contain enough investigation to determine whether Librela was responsible. Older dogs commonly have concurrent illness and may receive several medicines, which makes individual-case assessment difficult.
The VMD also reviewed reports in which osteoarthritis or similar joint disease appeared to progress faster than expected. The VMD classified those reports as very rare: fewer than 1 animal per 10,000 estimated animals treated. The agency cautioned that rapidly progressive osteoarthritis in dogs is not yet formally defined, that reports often lack serial imaging, and that severe pre-existing arthritis, weight, exercise, concurrent drugs, and off-label use can affect the apparent progression. The VMD’s full assessment explains those limitations.
| Question | Regulatory finding | Most defensible interpretation |
|---|---|---|
| Were deaths reported? | Yes. Death, including euthanasia, appeared as an outcome in some FDA cases. | Deaths occurred after treatment in reported cases; the reports alone do not prove Librela caused the deaths. |
| Is there a published confirmed fatality rate? | No reliable population fatality rate was established in the reviewed sources. | Do not convert FDA case counts into a percentage or call every reported death a Librela-caused death. |
| What did the UK estimate? | Death reports were estimated at 1 to 10 per 10,000 estimated treated animals. | This is an estimated reporting frequency with substantial uncertainty, not confirmed drug-caused mortality. |
| Was unusually rapid arthritis progression reported? | Yes. The VMD classified such reports as fewer than 1 per 10,000 estimated treated animals. | The signal deserves veterinary assessment, but the condition is not formally defined and causation remains unclear. |
Can Librela cause paralysis or seizures?
Paralysis, paresis, seizures, ataxia, weakness, and other neurologic signs have been reported after Librela, and the January 2026 UK product information lists paresis, paralysis, and seizures as very rare adverse events. A product-information listing means the event is recognized in safety monitoring; it does not prove that Librela caused every individual case.
The UK product-information summary lists these categories:
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware match| UK frequency category | Events listed for Librela | What owners should do with the information |
|---|---|---|
| Uncommon | Injection-site reactions such as swelling or warmth. | Tell the prescribing veterinarian, especially if the reaction is painful, spreading, or accompanied by other signs. |
| Rare | Diarrhea, vomiting, ataxia, excessive urination, urinary incontinence, loss of appetite, lethargy, and excessive thirst. | Contact the veterinarian for advice; urgency depends on severity, onset, hydration, and other symptoms. |
| Very rare | Hypersensitivity reactions including anaphylaxis, facial swelling, and itching; immune-mediated hemolytic anemia; immune-mediated polyarthritis; immune-mediated thrombocytopenia; paresis; paralysis; and seizures. | Seek prompt veterinary assessment. Collapse, a seizure, inability to stand, marked weakness, or paralysis warrants urgent attention. |
On February 3, 2026, the VMD announced that the product information for the 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg Librela products had been updated. The update added very rare reports of paresis, paralysis, and immune-mediated polyarthritis and advised caution in dogs with pre-existing immune-mediated hemolytic anemia, immune-mediated polyarthritis, or immune-mediated thrombocytopenia. The VMD safety update applies to UK product information; owners in the United States and other countries should consult the label and veterinarian applicable to their location.
The VMD summarized the broader principle this way: No medicine is 100% risk free.
The practical question for an individual dog is whether the expected pain and mobility benefit still outweighs the dog’s current risks, symptoms, medical history, and available alternatives.
Rank #3
- Joint Health Supplement for Dogs: Cosequin is the #1 vet recommended retail joint health supplement brand, supporting joint health in dogs for over 25 years
- Contains Glucosamine for Dogs: Cosequin contains glucosamine hydrochloride (FCHG49) and sodium chondroitin sulfate (TRH122), plus methylsulfonylmethane (MSM). This unique combination of ingredients supports healthy joints
- For Any Breed or Size: Whether you have a young or senior dog, a small or large breed, Cosequin helps support their joint health
- Tasty Chews for Daily Use: Cosequin comes in a tasty chewable tablet, making daily administration easy and convenient
- Exceptional Quality: Cosequin is backed by science, undergoing thorough quality inspections to ensure your dog receives a safe, high-quality product. It is manufactured in the United States with globally sourced ingredients
Why can’t adverse-event reports prove causation?
Adverse-event reports can show that a problem was noticed after a dog received Librela, but a report by itself cannot show that Librela caused the problem. The FDA says a report may instead reflect an underlying disease, another drug, a medication error, incomplete information, reporting bias, or a non-drug cause.
Older dogs treated for osteoarthritis may already have spinal disease, vestibular disease, metabolic illness, cancer, infection, severe joint degeneration, or another neurologic condition. Weakness, wobbliness, difficulty standing, urinary accidents, pain, and reduced appetite can overlap across those conditions. A veterinary examination and, when indicated, diagnostic testing are needed to separate them.
Recommended Free Tools
| Type of information | What it can establish | What it cannot establish alone |
|---|---|---|
| Spontaneous report count | That a possible safety signal exists and that certain signs have been reported. | How often the signs occur among all treated dogs or whether Librela caused each case. |
| Regulator-estimated reporting frequency | A structured estimate based on reported cases and an estimated treated-animal denominator. | The number of confirmed drug-caused events or a precise individual dog’s risk. |
| Individual veterinary case assessment | A professional judgment about whether the timing, examination, tests, competing causes, and response to treatment support an association. | A universal conclusion that every similar event in another dog has the same cause. |
| Confirmed drug-caused outcome | A causal determination in a specific case when the evidence supports one. | A general population fatality rate unless the underlying study has a valid denominator and comparison method. |
The FDA also warns that spontaneous systems are affected by underreporting and publicity-related reporting bias. A rise in reports can reflect increased awareness as well as a change in the medicine’s underlying risk. A low number of reports can reflect incomplete reporting rather than proof of safety.
Does timing or concurrent medication change the concern?
Timing matters for an investigation, but timing alone does not prove causation. In the FDA’s focused review, many concerning signs were reported after the first dose and often within the first week, while other cases began later. Among cases in which death was reported as a sign or outcome, 94 followed the initial dose, 82 included reported concomitant product use, and the reported timing ranged from one day to more than one month.
The UK product-information summary states that there are no safety data on concurrent long-term NSAID and bedinvetmab use in dogs. The same summary discusses rapidly progressive osteoarthritis reported in humans receiving humanized anti-nerve-growth-factor monoclonal antibody therapy, particularly in some high-dose or long-term NSAID situations, while stating that dogs have no reported equivalent of the human condition.
This information does not prove that an NSAID-plus-Librela combination causes adverse outcomes in dogs. It does mean that a veterinarian should review every medicine, supplement, dose, duration, pre-existing disease, and reason for treatment before the next injection. Owners should not add, remove, or combine pain medicines without veterinary direction.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →What should I do if my dog is worse after Librela?
A dog that develops new or worsening joint swelling or pain after Librela should be assessed promptly by the prescribing veterinarian. The VMD advises that additional diagnostics and case-by-case discontinuation should be considered when new or increased joint swelling or pain follows treatment.
Rank #4
- Advanced Hip & Joint Support: Formulated with glucosamine and chondroitin, these hip and joint chews for dogs promote healthy hips and joints in dogs, potentially reducing stiffness and improving overall joint health
- Joint Pain Relief: Our dog joint supplement large breed includes natural ingredients known to alleviate joint pain and discomfort, making your dog's movements more comfortable
- Enhanced Mobility for Active Dogs: These dog glucosamine chews aid in maintaining joint flexibility, allowing your dog to stay active and enjoy a better range of motion during their daily activities
- Formulated for All Dogs: Created with every dog in mind, our dog chondroitin glucosamine chews are perfect for all ages and sizes—from playful puppies to wise seniors—so your loyal companion gets the nutrients they need at any stage of life
- Veterinarian Formulated & USA Made: Trust in the premium quality of our dog glucosamine and chondroitin supplement large dog, which are formulated by veterinarians and manufactured in the USA within an FDA-registered facility
- Treat severe neurologic signs as urgent. Contact an emergency veterinary service for a seizure, collapse, paralysis, inability to stand, rapidly worsening weakness, or a sudden major decline. Contact the veterinarian promptly for wobbliness, ataxia, urinary incontinence, new severe pain, or marked changes in appetite, thirst, urination, or energy.
- Do not make the next-dose decision alone. Do not assume that every new sign is a Librela reaction, but do not dismiss a concerning change. Ask the prescribing veterinarian whether the next monthly injection should be delayed, discontinued, or replaced after the dog has been examined.
- Prepare a precise timeline. Record the injection date, dose number, when each sign began, whether the dog improved or worsened, all prescription and non-prescription products, and any recent illness or injury. Take a video of walking, standing, rising, or unusual movement if doing so is safe.
- Bring the treatment details. The FDA asks that adverse-event reports include the dog’s full medical history, number of Librela doses, and vial lot number when available. The prescribing veterinary practice, Zoetis, or FDA channels can receive reports; the FDA’s Dear Veterinarian letter provides the reporting context.
- Expect competing causes to be investigated. Neurologic disease, spinal disease, vestibular disease, metabolic illness, cancer, infection, medication effects, and rapidly progressing arthritis can resemble a medication reaction. The veterinarian may recommend examination, laboratory work, imaging, or referral depending on the signs.
Why might a dog be worse after Librela?
A dog may be worse after Librela because of a possible adverse reaction, progression of osteoarthritis, a separate neurologic or systemic illness, an interaction or effect involving another medicine, or an injury that coincided with treatment. The timing of the injection is an important clue, not a diagnosis.
Rapidly worsening joint pain deserves particular attention because the VMD reviewed reports of unusually fast progression of osteoarthritis or similar joint disease. The VMD noted that those reports often lacked serial imaging and that severe pre-existing arthritis, body weight, exercise, concurrent medicines, and off-label use could complicate the picture. A veterinarian may need to determine whether the dog has painful joint swelling, a structural injury, spinal disease, a vestibular problem, or another cause before deciding whether Librela helped, failed, or should be stopped.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What can I give my dog instead of Librela?
There is no universally safest replacement for Librela, and owners should not substitute a supplement or another pain medicine without veterinary advice. A safer decision is an individualized, multimodal arthritis plan that matches the dog’s diagnosis, age, weight, immune history, other medicines, mobility goals, and response to treatment.
Free tools Windows power users keep installed
One-click scans. No signup required.
The American Animal Hospital Association’s pain-management guidance supports combining veterinary-directed medication with weight optimization, controlled activity, rehabilitation, environmental modification, and other appropriate interventions. AAHA’s nutritional guidance also supports nutritional assessment and appropriate therapeutic diets. Potential care paths include:
| Care path | Intended role | Important limitation or monitoring question |
|---|---|---|
| Veterinarian-directed pharmacologic treatment | Prescription pain control or management of the underlying condition. | The veterinarian must review kidney, liver, gastrointestinal, immune, and other risks, along with every concurrent medicine; the dossier does not support naming one universal replacement. |
| Weight optimization and therapeutic nutrition | Reduce mechanical load and support an overall arthritis plan. | Food changes and calorie targets should be individualized; nutrition does not treat an acute seizure, paralysis, or suspected drug reaction. |
| Omega-3 fatty acids or an appropriate therapeutic diet | Non-prescription or nutritional adjunctive support for some dogs with osteoarthritis. | AAHA describes nutraceutical evidence as low except for omega-3 fatty acid evidence in dogs; a supplement cannot replace veterinary assessment or prescription analgesia. |
| Controlled exercise and rehabilitation | Preserve strength, mobility, balance, and function within the dog’s tolerance. | Exercise should be adjusted for pain, weakness, neurologic signs, and structural disease; rehabilitation may include physical therapy, hydrotherapy, manual therapy, or other modalities. |
| Environmental modification | Improve safety and reduce slipping or jumping at home. | Non-slip ramps, secure footing, traction socks, toe grips, supportive harnesses, and suitable beds assist mobility but do not treat the cause of worsening symptoms. |
| Surgery or specialist referral | Address a structural lesion or obtain orthopedic or neurologic expertise. | Referral is especially relevant when examination or imaging suggests a structural problem that medication alone cannot correct. |
For a veterinarian-approved nutritional adjunct, a dog joint support supplement with transparent EPA/DHA omega-3 labeling is a more evidence-aware choice than an unspecified product. AAHA’s guidance still places supplements within multimodal care, not as a treatment for suspected Librela-related injury. Ask the veterinarian to review the ingredients before use.
For dogs whose main problem is loss of strength, balance, or safe movement, ask whether canine physical therapy, veterinary rehabilitation, or hydrotherapy is appropriate. A rehabilitation professional can help build a controlled exercise plan; rehabilitation is not a substitute for urgent investigation of paralysis, seizures, collapse, or a rapidly worsening illness.
Current pricing and access vary by country, dog weight, clinic, medicine, and referral availability. No single current price comparison is presented here because the available research does not verify local pricing or a universal replacement program.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Best Value
- Joint Health Supplement for Dogs - Cosequin is the #1 vet recommended retail joint health supplement brandâ–¼, supporting joint health in dogs for over 25 years.
- Contains Glucosamine for Dogs - Cosequin contains glucosamine hydrochloride (FCHG49) and sodium chondroitin sulfate (TRH122), plus methylsulfonylmethane (MSM). This unique combination of ingredients supports healthy joints.
- For Any Breed or Size - Whether you have a young or senior dog, a small or large breed, Cosequin helps support their joint health.
- Tasty Chews for Daily Use - Cosequin comes in a tasty chewable tablet, making daily administration easy and convenient.
- Exceptional Quality - Cosequin is backed by science, undergoing thorough quality inspections to ensure your dog receives a safe, high-quality product. It is manufactured in the United States with globally sourced ingredients.
What should owners ask the veterinarian?
A focused appointment can make the Librela decision more concrete. Ask the veterinarian:
- What diagnosis best explains the dog’s current pain, weakness, wobbliness, urinary changes, or mobility loss?
- Did any of the current signs exist before the injection, and does the timing make a medication association plausible?
- Could spinal, vestibular, metabolic, infectious, cancer-related, injury-related, or other disease explain the change?
- Does the dog have immune-mediated hemolytic anemia, immune-mediated polyarthritis, immune-mediated thrombocytopenia, or another condition that changes the risk discussion?
- Could any current NSAID, prescription, supplement, or recent medication change contribute to the signs?
- Is examination, laboratory testing, imaging, rehabilitation assessment, or specialist referral appropriate?
- Should Librela be continued, delayed, discontinued, or replaced, and what signs should trigger urgent care?
- Should the event be reported, and can the practice provide the number of doses and vial lot number?
What is the fairest conclusion about Librela?
Librela deserves careful monitoring rather than either blanket reassurance or a claim that every reported death proves toxicity. U.S. and UK regulators have documented serious reports involving neurologic signs, immune-mediated disease, worsening joint disease, and death or euthanasia. The UK has added or highlighted additional safety information, including very rare reports of paresis, paralysis, seizures, and immune-mediated polyarthritis.
The strongest responsible conclusion is narrower: serious events have been reported after Librela, regulators continue to investigate and update safety information, and the available spontaneous-report evidence cannot establish that Librela caused every event or provide a reliable fatality rate. Owners should seek prompt veterinary assessment for new neurologic signs, rapid decline, or worsening joint pain, and make the next-dose decision with a veterinarian who knows the dog’s full history.
Frequently Asked Questions
Is Librela safe for dogs?
Librela is the dog arthritis treatment under scrutiny. Librela, or bedinvetmab, is a monthly prescription injection for pain associated with canine osteoarthritis. Serious neurologic, immune-mediated, joint-disease, and death reports have been reviewed, but spontaneous reports do not prove Librela caused every event.
Can Librela cause paralysis or seizures?
Paralysis, paresis, and seizures are listed as very rare adverse events in the UK Librela product information updated in January and February 2026. A listing does not prove that Librela caused every individual case, so a dog with weakness, paralysis, wobbliness, or seizures needs prompt veterinary assessment.
Has Librela caused deaths in dogs?
Deaths and euthanasia have been reported after Librela, but the reports do not establish that Librela caused every death. The UK Veterinary Medicines Directorate estimated death reports at 1 to 10 animals per 10,000 estimated animals treated; that estimate is not a confirmed Librela-caused fatality rate.
Should I stop Librela if my dog is wobbly?
Do not stop or continue Librela without veterinary advice. Contact the veterinarian promptly for new or worsening joint pain, swelling, wobbliness, weakness, or urinary incontinence, and seek urgent care for seizures, collapse, paralysis, inability to stand, or rapid decline.
The Bottom Line
Bottom line: Librela is the dog arthritis treatment at the center of these reports. Serious neurologic, immune-mediated, joint-disease, and death reports warrant prompt veterinary attention, but report counts are not proof of causation and do not equal a fatality rate. Do not stop or continue Librela by guesswork; have the prescribing veterinarian review symptoms, timing, other medicines, underlying disease, and alternatives.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
